1-3 of 3
Thomas Delea, MBA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Economic Burden of Disease Progression Among Transplant Eligible Multiple Myeloma Patients Who Have Received at Least One Line of Therapy in the US

Rafael Fonseca, MD, May Hagiwara, PhD, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Jacqueline Buchanan, Thomas Delea, MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 2211.
https://doi.org/10.1182/blood-2019-123743
Published: 2019
Journal Articles

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Thomas Delea, MBA, MSIA, Nicholas Despiegel, Diana Boyko, Jordan Amdahl, Ze Cong, PhD MS, Jerald Radich, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4746.
https://doi.org/10.1182/blood-2018-99-115230
Published: 2018
Journal Articles

Burden of Disease Progression in Patients with Multiple Myeloma Who Have Received at Least One Line of Therapy in the US

May Hagiwara, PhD, Thomas Delea, MBA, MSIA, Sumeet Panjabi, PhD, Emre Yucel, PhD MSc, MBA, BSPharm, Rafael Fonseca, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4754.
https://doi.org/10.1182/blood-2018-99-117230
Published: 2018